Decisions, Decisions

In a unanimous decision yesterday, the US Supreme Court ruled in the Association for Molecular Pathology et al. v. Myriad Genetics case that human genes are not patent-eligible, though it also said that cDNA is eligible to be patented as it is not naturally occurring. The case centered on the BRCA1 and BRCA2 breast cancer genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.